Press Releases

For a full overview of our announcements and press releases, visit our Euronext Oslo Børs Newsweb

NewsWeb

Newest first
Oldest first

04/04/2018

VACCIBODY AS ANNOUNCES INFORMED CONSENT SIGNED BY FIRST PATIENT AND ENROLMENT PROCESS INITIATED IN THE CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL.

03/04/2018

Vaccibody calls for Annual General Meeting.

08/03/2018

VACCIBODY AS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION (CTA) FOR ITS CANCER NEOANTIGEN PHASE I/IIA TRIAL BY GERMAN REGULATORY AUTHORITIES (PAUL EHRLICH INSTITUTE (PEI)).

01/03/2018

VACCIBODY AS TO HOST CAPITAL MARKETS DAY IN OSLO ON 3rd APRIL 2018.

24/01/2018

Vaccibody AS announces conditional approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)) as well as approval by the central ethics committee in Heidelberg (Ethikkommission Medizinische Fakultät Heidelberg); Reiterates estimate to start cancer neoantigen trial in Q1, 2018.

Pages: 12345678910111213141516171819202122232425262728293031323334353637383940